Company Description
Alpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company.
It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases.
The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus.
It is also developing RUBY-3 that has completed Phase 1 clinical trial for the treatment of glomerulonephritis; and RUBY-4, which has completed Phase 1 clinical trial for the treatment of cytopenias.
The company was incorporated in 2007 and is headquartered in Seattle, Washington.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 142 |
| CEO | Dr. Mitchell H. Gold M.D. |
Contact Details
Address: 188 East Blaine St., Suite 200 Seattle, Washington 98102 United States | |
| Phone | 206-788-4545 |
| Website | alpineimmunesciences.com |
Stock Details
| Ticker Symbol | ALPN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001626199 |
| CUSIP Number | 02083G100 |
| ISIN Number | US02083G1004 |
| Employer ID | 20-8969493 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Mitchell H. Gold M.D. | Executive Chairman and Chief Executive Officer |
| Dr. Stanford Peng M.D., Ph.D. | President and Head of Research and Development |
| Paul Rickey | Senior Vice President, Chief Financial Officer, Treasurer and Secretary |
| M. Christina Yi | Chief Technology Officer |
| Temre Johnson | Head of IR and Corporate Communications |
| Dr. Remy Durand Ph.D. | Chief Business Officer |
| Dr. Wolfgang Dummer M.D., Ph.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 11, 2024 | SC TO-C | Filing |
| Apr 10, 2024 | SC14D9C | Filing |
| Apr 10, 2024 | SC TO-C | Filing |
| Apr 10, 2024 | SC14D9C | Filing |
| Apr 10, 2024 | 8-K | Current Report |
| Apr 5, 2024 | 8-K | Current Report |
| Mar 20, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 20, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 20, 2024 | 10-K | Annual Report |
| Mar 18, 2024 | 8-K | Current Report |